Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology
- PMID: 18980979
- PMCID: PMC2655731
- DOI: 10.1158/1078-0432.CCR-08-1387
Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology
Abstract
Purpose: A meta-analytic approach was used to estimate the frequency of: (a) microsatellite instability-high (MSI-H) phenotype in unselected ovarian cancers and (b) various histologic subtypes of mismatch repair (MMR)-deficient epithelial ovarian cancers.
Methods: A systematic search of the Medline electronic database was conducted to identify articles published between January 1, 1966, and December 31, 2007, that examined MMR deficiency in ovarian cancers. Data were extracted on the study population, sample size, MSI-H frequency, and histology of MMR-deficient ovarian tumors.
Results: The pooled proportion of MSI-H ovarian cancers was 0.12 [95% confidence interval (CI), 0.08-0.17] from 18 studies with 977 cases. The proportion of histologic subtypes in the pooled analysis from 15 studies with 159 cases was serous at 0.32 (95% CI, 0.20-0.44), mucinous at 0.19 (95% CI, 0.12-0.27), endometrioid at 0.29 (95% CI, 0.22-0.36), clear cell at 0.18 (95% CI, 0.09-0.28), and mixed at 0.24 (95% CI, 0.07-0.47). There was significant heterogeneity between studies.
Conclusions: The frequency of the MSI-H phenotype in unselected ovarian cancers approximates 12%. MMR-deficient ovarian cancers also seem to be characterized by an overrepresentation of nonserous histologic subtypes. Knowledge of histologic subtype may aid clinicians in identifying the relatively large proportion of ovarian cancers due to MMR defects; such knowledge has potential implications for medical management.
Conflict of interest statement
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Figures
Similar articles
-
Mismatch-repair deficiency, microsatellite instability, and lynch syndrome in ovarian cancer: A systematic review and meta-analysis.Gynecol Oncol. 2023 Mar;170:133-142. doi: 10.1016/j.ygyno.2022.12.008. Epub 2023 Jan 20. Gynecol Oncol. 2023. PMID: 36682091
-
Frequency of mismatch repair deficiency in ovarian cancer: a systematic review This article is a US Government work and, as such, is in the public domain of the United States of America.Int J Cancer. 2011 Oct 15;129(8):1914-22. doi: 10.1002/ijc.25835. Epub 2011 Apr 4. Int J Cancer. 2011. PMID: 21140452 Free PMC article.
-
Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation.Health Technol Assess. 2017 Sep;21(51):1-238. doi: 10.3310/hta21510. Health Technol Assess. 2017. PMID: 28895526 Free PMC article.
-
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD008766. doi: 10.1002/14651858.CD008766.pub3. Cochrane Database Syst Rev. 2022. PMID: 35866378 Free PMC article.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280. Health Technol Assess. 2001. PMID: 11701100
Cited by
-
The quiescent cellular state is Arf/p53-dependent and associated with H2AX downregulation and genome stability.Int J Mol Sci. 2012;13(5):6492-6506. doi: 10.3390/ijms13056492. Epub 2012 May 24. Int J Mol Sci. 2012. PMID: 22754379 Free PMC article. Review.
-
Targeting breast cancer stem cells directly to treat refractory breast cancer.Front Oncol. 2023 May 12;13:981247. doi: 10.3389/fonc.2023.981247. eCollection 2023. Front Oncol. 2023. PMID: 37251931 Free PMC article. Review.
-
Pathology of Hereditary Breast and Ovarian Cancer.Front Oncol. 2020 Sep 29;10:531790. doi: 10.3389/fonc.2020.531790. eCollection 2020. Front Oncol. 2020. PMID: 33117676 Free PMC article.
-
Emerging serine-threonine kinase inhibitors for treating ovarian cancer.Expert Opin Emerg Drugs. 2019 Dec;24(4):239-253. doi: 10.1080/14728214.2019.1696773. Expert Opin Emerg Drugs. 2019. PMID: 31755325 Free PMC article.
-
Heterogeneity and treatment landscape of ovarian carcinoma.Nat Rev Clin Oncol. 2023 Dec;20(12):820-842. doi: 10.1038/s41571-023-00819-1. Epub 2023 Oct 2. Nat Rev Clin Oncol. 2023. PMID: 37783747 Review.
References
-
- American Cancer Society. Cancer facts and figures 2006. Atlanta: American Cancer Society; 2006.
-
- Boyd J, Rubin SC. Hereditary ovarian cancer: molecular genetics and clinical implications. Gynecol Oncol. 1997;64:196–206. - PubMed
-
- Bewtra C, Watson P, Conway T, Read-Hippee C, Lynch HT. Hereditary ovarian cancer: a clinicopathological study. Int J Gynecol Pathol. 1992;11:180–7. - PubMed
-
- Akiyama Y, Sato H, Yamada T, et al. Germ-line mutation of the hMSH6/GTBP gene in an atypical hereditary nonpolyposis colorectal cancer kindred. Cancer Res. 1997;57:3920–3. - PubMed
-
- Bronner CE, Baker SM, Morrison PT, et al. Mutation in the DNA mismatch repair gene homologue hMLH1 is associated with hereditary non-polyposis colon cancer. Nature. 1994;368:258–61. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical